Longevity science: how to tell evidence from hype

Creator: Halftime Health
Keywords: longevity evidence vs hype, evaluating longevity research, longevity claims framework, longevity hype filter, how to evaluate longevity research, longevity science framework

The short version: real longevity claims are rare, slow to confirm, and almost always smaller than the headline. Here is a framework that holds up.

TL;DR

Most longevity claims are based on animal or cell-culture studies, not human trials.
Human aging is measured in surrogates — biomarkers — not in years lived.
The right question is “what changed in whom, for how long, with what side effects.”

What it is

Longevity science is the field that studies why bodies age and what might slow that process down. It draws on several disciplines (in plain English: cell biology, genetics, epidemiology, and clinical medicine), and the published research ranges from yeast cells to small human trials. The headlines compress all of that into single sentences. The reality is messier.

How it works

Think of a longevity claim as a relay race. The first runner is a cell-culture or yeast study. The second runner is a worm or mouse study. The third is a small human trial. The fourth is a large randomized human trial. Most claims you see in the news are still in the first or second leg. They have not handed the baton to the human runners yet (López-Otín et al., Cell, 2013).

Who asks about it

People come to this question after reading something dramatic about a peptide, drug, or supplement that “extends lifespan.” Most want a way to know whether the claim deserves their attention or their savings.

What the research says

The honest map of the field looks like this. Lifespan extension in worms and mice is real and reproducible for several compounds, including rapamycin and metformin. Lifespan extension in humans has not been demonstrated for any drug or peptide. Healthspan signals — better function, fewer hospitalizations — are easier to study and are starting to appear for select interventions, but most of those data sets are still small (López-Otín et al., Cell, 2023). A claim that ignores this hierarchy is hype.

What to know before considering it

The questions worth asking before believing a longevity claim: Was it human or animal data? Was the sample size larger than 100 people? Did it measure something real or a surrogate marker? Was the trial randomized and controlled? About 9 in 10 compounds that extend lifespan in animal models do not replicate in humans. Skepticism is warranted.

The Halftime POV

Halftime is built for the second half of life, not the first vitamin shelf at the airport. The most useful longevity tools we have today are unsexy: sleep, strength, blood pressure control, and metabolic health. Anything beyond that should pass the four-question filter before it earns a place in your routine.

Related reading:

FAQ

Q: How do I evaluate a longevity claim? A: Ask three questions. Was it studied in humans or just animals or cells? Did it measure a real outcome — death, disease, function — or a surrogate marker? Was the sample size big enough that the result is unlikely to be chance?

Q: Why does animal-vs-human matter so much? A: Most aging compounds extend lifespan in mice or worms long before any human signal appears. Mice are not small humans. About 9 in 10 compounds that extend lifespan in animal models do not replicate in humans.

Q: What is a surrogate marker? A: A surrogate marker is a stand-in for a real outcome. Lower LDL cholesterol is a surrogate; fewer heart attacks is the real outcome. Many longevity studies measure surrogates because real outcomes take decades to track.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.